MGN 1601

Drug Profile

MGN 1601

Alternative Names: MGN-1601

Latest Information Update: 23 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mologen
  • Class Cancer vaccines; Cell therapies; Gene therapies; Tumour cell vaccines
  • Mechanism of Action Cell replacements; Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Renal cancer

Most Recent Events

  • 09 Jun 2016 Suspended - Phase-I/II for Renal cancer (Late-stage disease) in Germany (Intradermal)
  • 16 Sep 2015 Phase-I/II development is ongoing for Renal cancer in Germany
  • 07 May 2014 Further efficacy data from a phase I/II trial in Renal cancer released by Mologen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top